Medtronic exceeds fiscal second-quarter earnings and revenue expectations.

PHOENIX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Air Group, Inc. (“Mesa” or the “Company”) (Nasdaq: MESA) announced today that shareholders approved all proposals presented at the Company's special meeting of shareholders, including the proposal to adopt the agreement and plan of merger with Republic Airways Holdings Inc. (“Republic”)

PHILADELPHIA , Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of Heidrick & Struggles International, Inc. (NASDAQ: HSII) (“Heidrick”) stockholders to determine whether the buyout price undervalues the company's shares.

PHILADELPHIA , Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating the recently announced proposed buyout of Electronic Arts Inc. (NASDAQ: EA) (“EA” or the "Company") shareholders to determine whether the buyout agreement is fair to the Company's investors.

TEL AVIV, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE), an automotive technology company that develops software-defined vehicle (SDV) technology solutions, today announced a strategic collaboration with Mitsubishi Fuso Truck and Bus Corporation (Mitsubishi Fuso) through a memorandum of understanding (MoU)1 to collaborate and develop a software-defined vehicle (SDV) using REE's zonal SDV architecture and x-by-wire (XBW) technology. A one-year evaluation phase has commenced with the two companies working together to convert a Mitsubishi Fuso eCanter electric truck into an SDV, powered by REE's Zonal Architecture SDV technology. This collaboration permits Mitsubishi Fuso to assess the …

ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026.

Advancing U.S. Microelectronics Leadership Through Strategic Collaboration Advancing U.S. Microelectronics Leadership Through Strategic Collaboration

Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - NexMetals Mining Corp. (TSXV: NEXM) (NASDAQ: NEXM) ("NEXM" or the "Company") announces that it has granted annual equity incentive awards to certain directors, officers, employees and consultants pursuant to the Company's Omnibus Equity Incentive Plan (the "Plan"). The Board of Directors has approved the grant of restricted share units ("RSUs") representing an aggregate of 332,512 common shares to certain officers, employees and consultants.

EN 9120 aerospace certification elevates quality, traceability and compliance for distribution of commercial aircraft parts.

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Methanex Corporation (the “Company” or “Methanex”) (TSX:MX) (Nasdaq:MEOH) announced today that its Board of Directors has declared a quarterly dividend of US$0.185 per share. The dividend will be payable on December 31, 2025, to holders of common shares of record on December 17, 2025.

New design enhances water loop cleanliness and enables removal of in-row CDUs in high density applications, optimizing PUE and freeing space for additional IT racks. RACINE, Wis.

Total revenues of US$150.5 million exceeded guidance, up 104.4% YoY Bitcoin mining revenues reached US$30.6 million, up 241.0 % YoY Cryptocurrency treasury[1] climbed to a milestone of 1,610 BTC and 3,950 ETH as of October-end 2025 SINGAPORE , Nov. 18, 2025 /PRNewswire/ -- Canaan Inc. (NASDAQ: CAN) ("Canaan" or the "Company"), an innovator in crypto mining, today announced its unaudited financial results for the three months ended September 30, 2025. Third Quarter 2025 Operating and Financial Highlights Total revenues surged to US$150.5 million, exceeding the high-end of the Company's previous guidance range, representing 104.4% year-over-year and 50.2% quarter-over-quarter growth, underpinned …

TEL AVIV, Israel , Nov. 18, 2025 /PRNewswire/ -- RADCOM Ltd. (Nasdaq: RDCM) announced today that it has secured a contract for its Smart Network Visibility Solution through Rakuten Symphony for a leading mobile operator.

REHOVOT, Israel , Nov. 18, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 26, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics.

Protiviti is honored by Microsoft for outstanding achievement and innovation MENLO PARK, Calif. , Nov. 18, 2025 /PRNewswire/ -- Global consulting firm Protiviti has been selected for the AI Business Solution's 2025-2026 Microsoft Inner Circle.

Strengthens Intellectual Property Portfolio and Provides Protection for Therapeutic Combination in Acclaim-3 Clinical Trial AUSTIN, Texas , Nov. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the United States Patent and Trademark Office (USPTO) has granted Genprex a patent that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq®, through 2037. "We continue to build protection around our lead drug candidate, REQORSA, and this new …

More Than Half Plan to Expand Their Businesses, While Many Remain Worried About Inflation, Interest Rates, Supply Chains and Healthcare Costs CHARLOTTE, N.C. , Nov. 18, 2025 /PRNewswire/ -- Small and mid-sized business owners are cautiously optimistic about the coming year, with 74% expecting revenue increases and nearly 60% planning to expand their businesses, according to the 2025 Bank of America Business Owner Report, conducted in partnership with the Bank of America Institute.

EDAP to Present at Piper Sandler 37th Annual Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Tuesday, December 2 nd , 2025 AUSTIN, Texas, November 18, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Chief Executive Officer Ryan Rhodes is scheduled to present and, together with Chief Financial Officer Ken Mobeck, will host 1x1 investor meetings at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York City. Date: Tuesday, December 2nd Time: 10:30-10:55 am ET (fireside discussion) Format: Fireside discussion and 1x1 investor meetings …

LOS ANGELES , Nov. 18, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will be featured in a key opinion leader (KOL) webinar, "Redefining SoC in Complicated Staph. aureus Bacteremia to Unlock a Real Opportunity" on November 25 th, 2025 at 10:00am EST.

MONTRÉAL, Nov. 18, 2025 /PRNewswire/ - BCE Inc. (TSX: BCE) (NYSE: BCE) today announced that none of its fixed rate Cumulative Redeemable First Preferred Shares, Series R (Series R Preferred Shares) will be converted into floating rate Cumulative Redeemable First Preferred Shares, Series Q (Series Q Preferred Shares) on December 1, 2025. On October 17, 2025, BCE notified holders of Series R Preferred Shares that they could elect to convert their shares into Series Q Preferred Shares subject to the terms and conditions attached to those shares.